NCT00000755 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3


Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Genentech Glaxo Wellcome	Phases: Phase I
Indications	Acronym:
HIV Infections
Age Groups: Child Adult Senior	Gender: Both
Names: Biological: rgp120/HIV-1MN Drug: Zidovudine	Enrollment: 168

Additional information about NCT00000755.